The biopharmaceutical sector has been changing very rapidly from monoclonal antibodies to cell and gene therapy and RNA-based therapeutics. The growing healthcare needs demand cost-effective and rapid manufacturing technologies. The approval of biosimilars and continuous manufacturing has joined hands with manufacturers to meet these demands. This shift from fixed stainless steel to single-use systems (SUS) has revolutionized the therapeutic market. The rapid market growth for single-use systems, composed primarily of plastic components that are sealed and sterilized using gamma irradiation, is expected to continue. This webinar focuses on product development, including sterilization and lab-testing strategies, to help ensure that there is no contamination in the development and manufacturing of single-use systems, ultimately to promote end-user safety.